DaVita HealthCare Partners (DVA) Earns Media Sentiment Rating of 0.11
Press coverage about DaVita HealthCare Partners (NYSE:DVA) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DaVita HealthCare Partners earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.9235308003296 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Recent Analysis Shows OncoSec Medical, Synchrony, DaVita, Capital One, TransEnterix, and Hess Market Influences – Renewed Outlook, Key Drivers of Growth (finance.yahoo.com)
- DaVita Joins Patients in Urging Congress to Pass the Bipartisan Dialysis PATIENTS Demonstration Act (finance.yahoo.com)
- DaVita Boosts Efforts to Educate During National Diabetes Month (finance.yahoo.com)
- The Everett Clinic Plays a Leading Role in Addressing Opioid Epidemic (finance.yahoo.com)
- Integrated Care Improves Dialysis Patient Clinical Outcomes (finance.yahoo.com)
Several analysts have recently commented on DVA shares. J P Morgan Chase & Co cut DaVita HealthCare Partners from a “neutral” rating to an “underweight” rating in a research report on Monday, October 9th. Wolfe Research raised DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a research report on Monday, October 23rd. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $64.00 target price on shares of DaVita HealthCare Partners in a research report on Wednesday, September 6th. Zacks Investment Research cut DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, SunTrust Banks, Inc. set a $57.00 target price on DaVita HealthCare Partners and gave the stock a “hold” rating in a research report on Sunday, October 15th. Four analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the stock. DaVita HealthCare Partners currently has a consensus rating of “Hold” and a consensus target price of $65.00.
Shares of DaVita HealthCare Partners (NYSE DVA) opened at $59.91 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.45 and a debt-to-equity ratio of 1.69. The stock has a market cap of $11.38 billion, a PE ratio of 16.35, a price-to-earnings-growth ratio of 4.48 and a beta of 0.98.
DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 1st. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.02. DaVita HealthCare Partners had a return on equity of 14.02% and a net margin of 8.68%. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the prior year, the firm earned $1.01 EPS. The business’s quarterly revenue was up 4.3% on a year-over-year basis. equities research analysts anticipate that DaVita HealthCare Partners will post 3.54 earnings per share for the current fiscal year.
DaVita HealthCare Partners announced that its board has approved a stock repurchase plan on Tuesday, October 10th that allows the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.
DaVita HealthCare Partners Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.